WO1998031355A2 - Composition pharmaceutique - Google Patents

Composition pharmaceutique Download PDF

Info

Publication number
WO1998031355A2
WO1998031355A2 PCT/GB1998/000105 GB9800105W WO9831355A2 WO 1998031355 A2 WO1998031355 A2 WO 1998031355A2 GB 9800105 W GB9800105 W GB 9800105W WO 9831355 A2 WO9831355 A2 WO 9831355A2
Authority
WO
WIPO (PCT)
Prior art keywords
npa
pack
disease
dosage
physiologically acceptable
Prior art date
Application number
PCT/GB1998/000105
Other languages
English (en)
Other versions
WO1998031355A3 (fr
Inventor
Dereck Alan Woodcock
Original Assignee
Britannia Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Limited filed Critical Britannia Pharmaceuticals Limited
Publication of WO1998031355A2 publication Critical patent/WO1998031355A2/fr
Publication of WO1998031355A3 publication Critical patent/WO1998031355A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

La présente invention concerne un médicament destiné au traitement de la maladie de Parkinson, lequel se présente sous la forme d'un emballage contenant une dose de sels physiologiquement acceptables de N-propyl norapomorphine (NPA) ou de promédicaments de ceux-ci et une dose d'un inhibiteur de catéchol-O-méthyl-transférase (COMT).
PCT/GB1998/000105 1997-01-16 1998-01-14 Composition pharmaceutique WO1998031355A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9700855A GB2321190B (en) 1997-01-16 1997-01-16 Pharmaceutical composition
GB9700855.1 1997-01-16

Publications (2)

Publication Number Publication Date
WO1998031355A2 true WO1998031355A2 (fr) 1998-07-23
WO1998031355A3 WO1998031355A3 (fr) 1998-09-11

Family

ID=10806094

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/000105 WO1998031355A2 (fr) 1997-01-16 1998-01-14 Composition pharmaceutique

Country Status (2)

Country Link
GB (1) GB2321190B (fr)
WO (1) WO1998031355A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001984A1 (fr) * 1999-06-30 2001-01-11 Orion Corporation Preparation pharmaceutique a base de levodopa/carbidopa/entacapone
WO2003043974A2 (fr) * 2001-11-19 2003-05-30 Orion Corporation Nouveaux composes pharmaceutiques

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3947103B2 (ja) * 2000-07-14 2007-07-18 エフ．ホフマン−ラ ロシュ アーゲー 肝細胞毒性に対する素因を検出する方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2373530A1 (fr) * 1976-12-13 1978-07-07 Sterling Drug Inc Diesters de n-propylnorapomorphine, et leur utilisation comme medicaments
US4469695A (en) * 1980-02-25 1984-09-04 Ayerst, Mckenna & Harrison, Inc. 2-(4-Hydroxyalkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
WO1996037226A2 (fr) * 1995-05-26 1996-11-28 Pfizer Inc. Combinaisons pour le traitement de la maladie de parkinson contenant des antagonistes de nmda

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717643A (en) * 1967-05-04 1973-02-20 Sterling Drug Inc N-substituted-norapomorphines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2373530A1 (fr) * 1976-12-13 1978-07-07 Sterling Drug Inc Diesters de n-propylnorapomorphine, et leur utilisation comme medicaments
US4469695A (en) * 1980-02-25 1984-09-04 Ayerst, Mckenna & Harrison, Inc. 2-(4-Hydroxyalkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
WO1996037226A2 (fr) * 1995-05-26 1996-11-28 Pfizer Inc. Combinaisons pour le traitement de la maladie de parkinson contenant des antagonistes de nmda

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COUDORE ET AL: "Effect of Tolcapone on Plasma and Striatal Apomorphine Disposition in Rats" NEUROREPORT, vol. 8, no. 4, 3 March 1997, pages 877-880, XP002065840 *
KOPIN: "The Pharmacology of Parkinson's Disease Therapy: An Update" ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, vol. 33, 1993, pages 467-495, XP002065844 *
KUNTZER ET AL: "Treatment of Parkinson's Disease" EUROPEAN EUROLOGY, vol. 36, no. 6, November 1996, pages 396-408, XP002065845 *
LIMOUSIN ET AL: "Acute Administration of Levodopa-Benserazide and Tolcapone, a COMT Inhibitor, in Parkinson's Disease" CLINICAL NEUROPHARMACOLOGY, vol. 18, no. 3, 1995, pages 258-265, XP002065842 *
MCKENZIE AND WHITE: "Evidence for the Methyation of Apomorphine by Catechol-O-Methyl-Transferase in vivo and in vitro" BIOCHEMICAL PHARMACOLOGY, vol. 22, 1973, pages 2329-2336, XP002065841 *
T\RNWALL AND MANNISTO: "Effects of Three Types of Catechol O-Methylation Inhibitors on L-3,4-Dihydroxyphenylalanine-Induced Circling Behavior in Rats" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 250, no. 1, 1993, pages 77-84, XP002065843 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001984A1 (fr) * 1999-06-30 2001-01-11 Orion Corporation Preparation pharmaceutique a base de levodopa/carbidopa/entacapone
US6500867B1 (en) 1999-06-30 2002-12-31 Orion Corporation Pharmaceutical composition comprising entacapone, levodopa, and carbidopa
US6797732B2 (en) 1999-06-30 2004-09-28 Orion Corporation Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
KR100905428B1 (ko) * 1999-06-30 2009-06-30 오리온 코포레이션 레보도파/카비도파/엔타카폰 약학적 제제
CZ303010B6 (cs) * 1999-06-30 2012-02-29 Orion Corporation (Bic 1999212-6) Perorální pevná kompozice obsahující entacapon, levodopu a karbidopu, zpusoby její prípravy a použití
CZ304416B6 (cs) * 1999-06-30 2014-04-23 Orion Corporation Farmaceutická kompozice obsahující entacapon, levodopu a karbidopu a léčivo pro léčení Parkinsonovy choroby
WO2003043974A2 (fr) * 2001-11-19 2003-05-30 Orion Corporation Nouveaux composes pharmaceutiques
WO2003043974A3 (fr) * 2001-11-19 2003-07-17 Orion Corp Nouveaux composes pharmaceutiques

Also Published As

Publication number Publication date
WO1998031355A3 (fr) 1998-09-11
GB2321190B (en) 2000-09-20
GB9700855D0 (en) 1997-03-05
GB2321190A (en) 1998-07-22

Similar Documents

Publication Publication Date Title
JP2572768B2 (ja) レボドパメチルエステルを有効成分とするパ−キンソン病治療剤
JP6889231B2 (ja) レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法
CN101600438B (zh) 疼痛疾病治疗剂
TW389696B (en) Accelerated release composition containing bromocriptine
US4822802A (en) Method of fentanly administration for postoperative pain relief
EP2746251A3 (fr) Promédicaments hydrosolubles positivement chargés d'acétaminophène et composés associés à vitesse de pénétration cutanée très rapide
CA2393437A1 (fr) Formulation a base d'exo-s-mecamylamine et utilisation en traitement
JP2021503468A5 (fr)
CA2661759A1 (fr) Cachet de buprenophine comme traitement de substitution lie a la toxicomanie
KR20050120753A (ko) 경점막 약물 전달 시스템
RU2007122410A (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda-рецептора, способ введения такого nmda-антагониста субъекту
WO2012006283A1 (fr) Compositions et procédés pour la modulation de la pharmacocinétique et de la pharmacodynamie de l'insuline
RU2007133435A (ru) Способ комбинированного лечения и применимые для этого сочетания лекарственных средств
JP2007509146A (ja) レボドーパの持続効果のための組成物及び投与形
CA2403994A1 (fr) Administration nasale d'agents pour traiter la gastroparesie
EP3331509B1 (fr) Solution injectable liquide stable de midazolam et de pentazocine
Nesek Adam et al. Pain management in critically ill patients
US20060110333A1 (en) Composition for nasal absorption
US3557292A (en) Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine
CN107137417B (zh) 一种用于治疗恶病质的药物组合物及其应用
WO1998031355A2 (fr) Composition pharmaceutique
KR20090125748A (ko) 대상포진 후 신경통 치료용 정제 및 대상포진 후 신경통의 치료 방법
US11819485B2 (en) Levodopa fractionated dose composition and use
JP2001508769A (ja) アレンドロン酸塩及び胃排出を促進する薬剤を含有する医薬組成物
JP3415643B2 (ja) 筋ジストロフィー症治療薬

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA GB JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA GB JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998533930

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09582650

Country of ref document: US

122 Ep: pct application non-entry in european phase